Regulation of Renal Phosphate Transport by FGF23 is Mediated by FGFR1 and FGFR4

Overview

Journal Am J Physiol Renal Physiol

Publisher American Physiological Society

Specialties Nephrology
Physiology

Date 2013 Nov 22

PMID 24259513

Citations 52

Authors

Jyothsna Gattineni

Priyatharshini Alphonse

Qiuyu Zhang

Nisha Mathews

Carlton M Bates

Michel Baum

Affiliations

Soon will be listed here.

Abstract

Fibroblast growth factor 23 (FGF23) is a bone-derived hormone that acts on the proximal tubule to decrease phosphate reabsorption and serum levels of 1,25-dihydroxyvitamin D₃ [1,25(OH)₂ Vitamin D₃]. Abnormal FGF23 metabolism has been implicated in several debilitating hypophosphatemic and hyperphosphatemic disorders. The renal receptors responsible for the phosphaturic actions of FGF23 have not been elucidated. There are four fibroblast growth factor receptors (FGFR); 1-4 with "b" and "c" isoforms for receptors 1, 2, and 3. FGFR1, 3, and 4 are expressed in the mouse proximal tubule, and deletion of any one receptor did not affect serum phosphate levels, suggesting that more than one receptor is involved in mediating the phosphaturic actions of FGF23. To determine the receptors responsible for the phosphaturic actions of FGF23, we studied Fgfr1 (kidney conditional) and Fgfr4 (global) double mutant mice (Fgfr1⁻/⁻/Fgfr4⁻/⁻). Fgfr1⁻/⁻/Fgfr4⁻/⁻ mice have higher FGF23 levels than their wild-type counterparts (108.1 ± 7.3 vs. 4,953.6 ± 675.0 pg/ml; P < 0.001). Despite the elevated FGF23 levels, Fgfr1⁻/⁻/Fgfr4⁻/⁻ mice have elevated serum phosphorus levels, increased brush-border membrane vesicle (BBMV) phosphate transport, and increased Na-P(i) cotransporter 2c (NaPi-2c) protein expression compared with wild-type mice. These data are consistent with FGFR1 and FGFR4 being the critical receptors for the phosphaturic actions of FGF23.

Citing Articles

The role of fibroblast growth factor 23 in regulation of phosphate balance.

Wilson R, Mukherjee-Roy N, Gattineni J Pediatr Nephrol. 2024; 39(12):3439-3451.

PMID: 38874635 DOI: 10.1007/s00467-024-06395-5.

The Intricacies of Renal Phosphate Reabsorption-An Overview.

Walker V Int J Mol Sci. 2024; 25(9).

PMID: 38731904 PMC: 11083860. DOI: 10.3390/ijms25094684.

Safety Profile and Adverse Event Management for Futibatinib, An Irreversible FGFR1-4 Inhibitor: Pooled Safety Analysis of 469 Patients.

Meric-Bernstam F, Hollebecque A, Furuse J, Oh D, Bridgewater J, Shimura M Clin Cancer Res. 2024; 30(8):1466-1477.

PMID: 38329716 PMC: 11016890. DOI: 10.1158/1078-0432.CCR-23-2646.

Discovery of lirafugratinib (RLY-4008), a highly selective irreversible small-molecule inhibitor of FGFR2.

Schonherr H, Ayaz P, Taylor A, Casaletto J, Toure B, Moustakas D Proc Natl Acad Sci U S A. 2024; 121(6):e2317756121.

PMID: 38300868 PMC: 10861881. DOI: 10.1073/pnas.2317756121.

RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations.

Subbiah V, Sahai V, Maglic D, Bruderek K, Toure B, Zhao S Cancer Discov. 2023; 13(9):2012-2031.

PMID: 37270847 PMC: 10481131. DOI: 10.1158/2159-8290.CD-23-0475.

References

Prabhu S, Levi M, Dwarakanath V, Arar M, Biber J, Murer H . Effect of glucocorticoids on neonatal rabbit renal cortical sodium-inorganic phosphate messenger RNA and protein abundance. Pediatr Res. 1997; 41(1):20-4. DOI: 10.1203/00006450-199701000-00003. View

Kawata T, Imanishi Y, Kobayashi K, Miki T, Arnold A, Inaba M . Parathyroid hormone regulates fibroblast growth factor-23 in a mouse model of primary hyperparathyroidism. J Am Soc Nephrol. 2007; 18(10):2683-8. DOI: 10.1681/ASN.2006070783. View

Perry W, Stamp T . Hereditary hypophosphataemic rickets with autosomal recessive inheritance and severe osteosclerosis. A report of two cases. J Bone Joint Surg Br. 1978; 60-B(3):430-4. DOI: 10.1302/0301-620X.60B3.681423. View

. A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. The HYP Consortium. Nat Genet. 1995; 11(2):130-6. DOI: 10.1038/ng1095-130. View

Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K . The Antisenescence Protein Klotho Is Necessary for FGF23-Induced Phosphaturia Klotho Converts Canonical FGF Receptor into a Specific Receptor for FGF23.Nature 444: 770-774, 2006. J Am Soc Nephrol. 2023; 18(3):663-669. DOI: 10.1681/01.asn.0000926868.48235.3d. View

Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T . Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest. 2004; 113(4):561-8. PMC: 338262. DOI: 10.1172/JCI19081. View

Mohammadi M, Olsen S, Ibrahimi O . Structural basis for fibroblast growth factor receptor activation. Cytokine Growth Factor Rev. 2005; 16(2):107-37. DOI: 10.1016/j.cytogfr.2005.01.008. View

Liu S, Vierthaler L, Tang W, Zhou J, Quarles L . FGFR3 and FGFR4 do not mediate renal effects of FGF23. J Am Soc Nephrol. 2008; 19(12):2342-50. PMC: 2588103. DOI: 10.1681/ASN.2007121301. View

Engleka K, Gitler A, Zhang M, Zhou D, High F, Epstein J . Insertion of Cre into the Pax3 locus creates a new allele of Splotch and identifies unexpected Pax3 derivatives. Dev Biol. 2005; 280(2):396-406. DOI: 10.1016/j.ydbio.2005.02.002. View

10.

Arar M, Levi M, Baum M . Maturational effects of glucocorticoids on neonatal brush-border membrane phosphate transport. Pediatr Res. 1994; 35(4 Pt 1):474-8. View

11.

Jonsson K, Zahradnik R, Larsson T, White K, Sugimoto T, Imanishi Y . Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med. 2003; 348(17):1656-63. DOI: 10.1056/NEJMoa020881. View

12.

Lorenz-Depiereux B, Bastepe M, Benet-Pages A, Amyere M, Wagenstaller J, Muller-Barth U . DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nat Genet. 2006; 38(11):1248-50. PMC: 5942547. DOI: 10.1038/ng1868. View

13.

Gattineni J, Baum M . Regulation of phosphate transport by fibroblast growth factor 23 (FGF23): implications for disorders of phosphate metabolism. Pediatr Nephrol. 2009; 25(4):591-601. PMC: 3151467. DOI: 10.1007/s00467-009-1273-z. View

14.

Perwad F, Zhang M, Tenenhouse H, Portale A . Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1alpha-hydroxylase expression in vitro. Am J Physiol Renal Physiol. 2007; 293(5):F1577-83. DOI: 10.1152/ajprenal.00463.2006. View

15.

Lavi-Moshayoff V, Wasserman G, Meir T, Silver J, Naveh-Many T . PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am J Physiol Renal Physiol. 2010; 299(4):F882-9. DOI: 10.1152/ajprenal.00360.2010. View

16.

Ornitz D, Itoh N . Fibroblast growth factors. Genome Biol. 2001; 2(3):REVIEWS3005. PMC: 138918. DOI: 10.1186/gb-2001-2-3-reviews3005. View

17.

Wohrle S, Bonny O, Beluch N, Gaulis S, Stamm C, Scheibler M . FGF receptors control vitamin D and phosphate homeostasis by mediating renal FGF-23 signaling and regulating FGF-23 expression in bone. J Bone Miner Res. 2011; 26(10):2486-97. DOI: 10.1002/jbmr.478. View

18.

Poladia D, Kish K, Kutay B, Hains D, Kegg H, Zhao H . Role of fibroblast growth factor receptors 1 and 2 in the metanephric mesenchyme. Dev Biol. 2006; 291(2):325-39. DOI: 10.1016/j.ydbio.2005.12.034. View

19.

Gattineni J, Twombley K, Goetz R, Mohammadi M, Baum M . Regulation of serum 1,25(OH)2 vitamin D3 levels by fibroblast growth factor 23 is mediated by FGF receptors 3 and 4. Am J Physiol Renal Physiol. 2011; 301(2):F371-7. PMC: 3154596. DOI: 10.1152/ajprenal.00740.2010. View

20.

Cai Q, Hodgson S, Kao P, Lennon V, Klee G, Zinsmiester A . Brief report: inhibition of renal phosphate transport by a tumor product in a patient with oncogenic osteomalacia. N Engl J Med. 1994; 330(23):1645-9. DOI: 10.1056/NEJM199406093302304. View